Abstract | Type 1 diabetes mellitus (T1DM) is an autoimmune disorder directed against the β cells of the pancreatic islets. The genetic risk of the disease is linked to HLA-DQ risk alleles and unknown environmental triggers. In most countries, only 10-15% of children or young adults newly diagnosed with T1DM have a firstdegree relative with the disease. Autoantibodies against insulin, GAD65, IA-2 or the ZnT8 transporter mark islet autoimmunity. These islet autoantibodies may already have developed in children of 1-3 years of age. Immune therapy in T1DM is approached at three different stages. Primary prevention is treatment of individuals at increased genetic risk. For example, one trial is testing if hydrolyzed casein milk formula reduces T1DM incidence in genetically predisposed infants. Secondary prevention is targeted at individuals with persistent islet autoantibodies. Ongoing trials involve nonautoantigen-specific therapies, such as Bacillus Calmette-Guérin vaccine or anti-CD3 monoclonal antibodies, or autoantigen-specific therapies, including oral and nasal insulin or alum-formulated recombinant human GAD65. Trial interventions at onset of T1DM have also included nonautoantigen-specific approaches, and autoantigen-specific therapies, such as proinsulin peptides. Although long-term preservation of β-cell function has been difficult to achieve in many studies, considerable progress is being made through controlled clinical trials and animal investigations towards uncovering mechanisms of β-cell destruction. Novel therapies that prevent islet autoimmunity or halt progressive β-cell destruction are needed.
Introduction
Type 1 diabetes mellitus (T1DM) is characterized by immune-mediated, specific destruction of the β cells of the pancreatic islets. The pathogenetic process begins years before the clinical onset, when the tolerance to self autoantigens is lost. The autoimmune destruction is chronic and continuous after clinical diagnosis. Eventually, after some 2-3 years of insulin therapy, essentially all β cells are destroyed, which results in an almost complete incapacity of patients with T1DM to produce insulin. Hence, the disease is fatal if not treated, as it is not possible to live without insulin. All patients with T1DM, therefore, need daily insulin injections to survive. However, the replacement therapy is inade quate because it is next to impossible to obtain a perfect balance between the insulin injected and the actual need for the hormone. Additionally, subcutaneous injections of insulin do not permit insulin to directly reach the liver, which is the first target organ of insulin secreted from β cells.
Ever since the discovery of insulin in 1921, it has been possible to keep patients alive with insulin replacement therapy. Importantly, the replacement therapy has been evolving continuously, as at present no other treatment can be offered to a patient newly diagnosed with T1DM. A variety of insulin analogues with different times of action, long-acting as well as short or rapid-acting analogues, have been on the market for the past decade. 1 These analogues combined with novel approaches for the administration of insulin, continuous glucose monitoring and improved devices for blood glucose testing has contributed to increased quality of life for patients with T1DM. However, none of the approaches to control T1DM with insulin analogues are addressing the underlying cause of T1DM. Considerable importance should, therefore, be directed towards designing controlled clinical trials to interfere with either the aetiology or the pathogenic processes involved in the eradication the β cells in patients with T1DM.
Current understanding of the aetiology and pathogenesis of T1DM have enabled the design of primary and secondary prevention trials and intervention trials of immune therapy. Knowledge of three main factors in individuals at risk of T1DM or who have been diagnosed with T1DM indicates which type of immune therapy approach to take. Immune intervention can be attempted at three main stages ( Figure 1 ). The first main factor is the genetic aetiology of T1DM, which involves inherited susceptibility to islet autoimmunity and T1DM. Individuals at increased genetic risk of islet autoimmunity would, therefore, be treated by a primary prevention approach. The objective would be to secure or induce immunological tolerance to islet autoantigens and, thereby, prevent subsequent destruction of β cells.
Second, islet autoimmunity is marked by the appearance of autoantibodies against specific autoantigens.
Individuals developing islet autoimmunity would be treated by a secondary prevention approach. The objective would be to prevent the loss of β cells either by inducing immunological tolerance to one or several islet autoantigens after the appearance of autoantibodies or inhibiting the autoimmune process, or both. Third, levels of C-peptide as a measure of residual β-cell function after the clinical onset of T1DM. Patients who have lost a sufficient number of β cells or β-cell function would be offered intervention therapy. As for the secondary prevention approach, the objective would be to prevent the loss of β cells either by inducing immunological tolerance to one or several islet autoantigens or inhibiting the autoimmune process directed against β cells, or both.
Genetic aetiology
The lifetime risk of T1DM in an individual who has a sib ling, a father or a mother with T1DM is ~8%, ~5% and ~3%, respectively. Genetic aetiology of T1DM is strongly linked to the HLA group of genes that are found on the short arm of chromosome 6.
2 Two extended HLA haplotypes exist, which are associated with a marked increased risk of T1DM ( Figure 1 , Box 1). Among white individuals, the extended HLA haplotypes DRB1*04-DQA1*03:01-B1*03:02 (DR4-DQ8) and DRB1*03:01-DQ A1*05:01-B1*02:1 (DR3-DQ2) alone or in combination may be present in nearly 90% of patients with T1DM diagnosed before 18 years of age. 2 The prevalence of the DR4-DQ8/DR3-DQ2 heterozygous genotype is 3.5% among all newborn babies in the population, whereas as many as 27-30% of patients with T1DM have this genotype. The risk of T1DM is further increased if an individual has these specific HLA haplotypes and has a family member with T1DM. Rapid onset of T1DM at <3-4 years of age is particularly associated with the DR4-DQ8/DR3-DQ2 heterozygous genotype. HLA genotyping alone could, therefore, be one possible approach to identify individuals for primary prevention trials. However, only a small fraction of individuals born with the DR4-DQ8/DR3-DQ2 heterozygous genotype will develop T1DM (in Sweden this figure is 6%). Increasing the odds for islet autoimmunity or T1DM by adding non-HLA genetic factors, such as PTPN22 and INS VNTR, to the inclusion criteria for primary prevention trials might be important.
Genome-wide association studies have identified more than 40 genetic factors associated with the risk of T1DM. 3 These investigations demonstrated that genetic risk of T1DM is primarily a result of HLA genotype. INS VNTR and possibly PTPN22 contribute to the genetic risk to the extent that it would be necessary to take these genetic factors into account when selecting individuals for clinical trials to prevent T1DM. The contributions of the remaining ~40 loci for either islet autoimmunity, T1DM, or both, remains to be determined.
Islet autoimmunity
Whereas HLA genotype is the strongest marker of the genetic aetiology of T1DM, islet autoantibodies are the strongest and currently the only available markers Key points ■ As an autoimmune disease, type 1 diabetes mellitus (T1DM) is strongly associated with mutations in HLA-DQ risk alleles; non-HLA genes contributing to disease risk are related to the immune system ■ Autoantibodies to the β-cell autoantigens insulin, GAD65, IA-2 and the ZnT8 transporter are major markers of islet autoimmunity; the number of islet autoantibodies determines risk and time to T1DM clinical onset ■ Immune therapy for T1DM is approached at three stages: primary prevention, secondary prevention and intervention ■ Primary prevention requires identification of newborn babies at increased genetic risk of T1DM; induction of immunological tolerance to islet autoantigens is a goal, but is difficult to measure ■ Nonautoantigen-specific or autoantigen-specific interventions can be used at the secondary prevention stage in individuals who have developed persistent islet autoantibodies; combination therapies have yet to be carried out ■ Immune therapy interventions at onset of T1DM can involve both nonautoantigen-specific and autoantigen-specific therapies; the most common primary outcome in clinical studies and trials is the preservation of C-peptide levels of islet autoimmunity and, therefore, of T1DM pathogenesis ( Figure 1, Box 1) . Currently, the risk of T1DM is predicted by the presence of autoantibodies against the following four β-cell proteins: insulin, GAD65, IA-2 and the ZnT8 transporter. 4, 5 The GADA, IA-2A and ZnT8A assays seem to be robust and are standardized. 6, 7 Only insulin autoantibody assays remain to be fully standardized. 8 The Immunology of Diabetes Society has begun efforts to harmonize and standardize cellular assays for islet autoimmunity, including both HLA class I and II restricted T-cell activities. 9 Both clinical studies and trials of immunotherapy for T1DM need to be multicentre investigations to have sufficient participants; therefore, standardization of assays to compare cellular responses to treatment is becoming increasingly important.
Analyses of islet autoantibodies in the general population, and among the children or siblings of patients with T1DM, can identify individuals with more than one islet autoantibody who can be included in secon dary
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Primary prevention Intervention Secondary prevention Figure 1 | Representation of type 1 diabetes mellitus aetiology and pathogenesis, which indicates the points at which primary prevention, secondary prevention or intervention can be attempted. The genetic risk is conferred by HLA genes on chromosome 6. Two haplotypes, DQA1*03:01-B1*03:02 and DQA1*05:01-B1*02:01, are the two major risk-determining factors. The appearance of islet autoimmunity is represented by autoantibodies against GAD65 (GADA), insulin (IAA), insulinoma antigen-2 (IA-2A) and ZnT8 (ZnT8A). Insulitis is considered a late event in the pathogenic process; therefore, it may take years for the clinical onset of type 1 diabetes mellitus.
prevention trials aimed at delaying or preventing T1DM. In individuals with a first-degree relative with T1DM, the presence of a single islet autoantibody only marginally increases the risk of T1DM. 4 However, the risk of T1DM increases with each additional islet auto antibodies ( Figure 2 ). Whereas 50% of individuals who have or have had two islet autoantibodies develop T1DM over 5 years, it will only take 3 years for 50% of indivi duals who have or have had more than three islet auto antibodies to develop the disease. 10 Prospective follow-up of individuals at risk of the development of persistent islet autoantibodies is, therefore, an effective approach to identify individuals who could be offered inclusion in se condary prevention trials.
The identification of individuals with islet autoantibodies makes it possible to follow-up these individuals until T1DM is diagnosed, to make observations on the natural history of the disease. This follow-up process is less beneficial to the patient than to be able to ask such individuals to participate in secondary prevention trials. Is there any benefit for an islet autoantibody-positive child or young adult to be followed up only to observe the inevitable loss of β-cell function? In the past few years, investigations in both the DAISY 11 and the TEDDY 12 studies demonstrate that diabetes mellitus is often diagnosed in observational clinical studies without the classic symptoms of T1DM. Hence, at the time of clinical diagnosis of diabetes mellitus the patients may still have a clinically significant β-cell reserve and would, therefore, benefit from low insulin doses compared with patients who are diagnosed when in ketoacidosis and with a major loss of endogenous insulin production. An early diagnosis of T1DM might, therefore, make it necessary to alter intervention trial end points.
11
C-peptide
A reduction in C-peptide levels indicates loss of β-cells and has already occurred at the time of clinical diagnosis. Although C-peptide levels are age-dependent and fall to levels well below the normal range by diagnosis of T1DM, it has been feasible and reliable to measure a reduction in the decrease in C-peptide levels. 13 The possibility of including children in intervention clinical trials when they have clinically significant residual β-cell function -these children often have C-peptide levels within the normal range in adults-might improve patient outcomes in intervention clinical trials. Ideally, the patients should need only low doses of insulin to control their blood glucose levels and maintain a normal HbA 1c level.
To date, none of the many intervention trials in T1DM has achieved a long-term reduction in the C-peptide disappearance rate. Some trials have achieved promising results, but in most trials the reduction in C-peptide disappearance rate has been transient. Although these clinical trials have improved our understanding of disease pathogenesis, a need exists for different approaches to achieve clinically significant and long-lasting prevention of C-peptide disappearance and β-cell loss in T1DM. In this Review, immune therapy trials of T1DM that are ongoing or that have been conducted in the past decade are discussed. 14, 15 These trials include primary prevention, secondary prevention or interventions studies.
Primary prevention
The design of primary prevention trials in T1DM is quite conjectural at present. Triggers of islet auto immunity have not been identified; therefore, researchers can only make intelligent guesses about what to treat to prevent islet autoimmunity. Any trial would aim at hindering triggers of islet autoimmunity in individuals with increased genetic susceptibility to T1DM. A current weakness is that the only markers of islet autoimmunity measured are the islet autoantibodies (insulin, GAD65, IA-2 and the ZnT8 transporter), measured as the IgG isoform, rather than as the IgM isoform or as both isoforms; measurement of the IgM isoforms might enable detection of islet autoimmunity closer to the time of the triggered event than is possible by detection of the IgG isoforms. The immune responses of antigen-presenting cells, T cells and B cells that are expected to precede the appearance of islet autoantibodies are yet to be discovered.
The approach to primary prevention could be nonautoantigen or autoantigen-specific. The effects of nonautoantigen-specific therapy will remain speculative until a trigger of islet autoimmunity has been identified. An autoantigen-specific therapy would address the question of whether immunological tolerance against islet autoantigens is induced early in life. Two major problems exist with primary prevention. First, at present, no accepted method exists to determine whether an indivi dual has developed immunological tolerance to an autoantigen. In other words, what approach could be taken to find out if there is a 'hole' in the immuno logical repertoire at about 1-2 years of age indicating a risk of a T-cell and B-cell-mediated immune response being Islet autoantibodies ‡ (percentage of patients with T1DM) (32) *HLA-DQ genotype represents 69% of patients diagnosed with T1DM.
‡ 93% of patients screened had at least one islet autoantibody. Data from the Swedish Better Diabetes Diagnosis study representing HLA-DQ genotyping and islet autoantibody analysis from more than 3,000 patients diagnosed with T1DM from May 2005 to August 2010. 81 ZnT8 autoantibodies were against the arginine, tryptophan or glutamine at position 325 in the translated protein. Abbreviation: T1DM, type 1 diabetes mellitus.
mounted against islet autoantigens? Second, immune tolerance induction may be safe but what would be the approach to find out if the treatment had been successful?
Nonautoantigen primary prevention Early exposure to cow's milk protein is hypothesized to increase the risk of T1DM. 16 Dietary manipulation using hydrolyzed casein milk formula has shown promise to reduce the risk of islet autoimmunity and T1DM in infants with an increased genetic risk of T1DM. 17 The TRIGR trial (Trial to Reduce Insulin-dependent Diabetes Mellitus in the Genetically at Risk) is an international effort involving 17 countries to test whether hydrolyzed casein milk formula reduces the risk of T1DM in genetically predisposed infants born in families with T1DM. 16 Following a period of 6-8 months of breastfeeding, infants were assigned to receive hydrolyzed casein-based milk formula or conventional cow's milk formula. The results will be available in 2017. 16 Vitamin D is speculated to protect against islet autoimmunity, T1DM, or both, 18 possibly through effects on T lymphocytes. 19 Low concentrations of vitamin D have been reported in children with T1DM, and low levels of vitamin D during pregnancy have been suggested to increase the risk of T1DM. 20 Supplementation with cod liver oil, an important source of vitamin D and omega-3 fatty acids, during the first year of life led to a reduced risk of T1DM in Norwegian children. However, no risk reduction was found with other kinds of vitamin D supplementation, which suggests that omega-3 fatty acids were responsible for the effect. 21 A clinical trial of cod liver oil in children with an increased susceptibility for islet autoimmunity, T1DM, or both would be warranted.
Nutritional Intervention to Prevent Diabetes (NIPDiabetes) is a pilot study to test a proposed preventive effect of oral docosahexanoic acid (DHA, an omega-3 fatty acid) against islet autoimmunity in utero and in early infancy. 22 This study is ongoing and includes pregnant mothers in their third trimester who have HLA-DQ risk alleles and have T1DM themselves or a family history of T1DM. Pregnant women have received DHA in late pregnancy and their offspring have received DHA in early infancy; the infants are being followed up for the development of islet autoantibodies during the first 5 years of life. The NIP-Diabetes study itself is not powered to detect an effect on the development of T1DM.
Screening newborn babies for HLA genotypes to identify children with increased risk of islet auto immunity and T1DM is feasible. 23, 24 In nonantigen primary prevention trials, limiting overtreatment by selecting children with HLA-DQ risk for islet autoimmunity and T1DM seems to be important. The authors believe that the outcome of the TRIGR study will help guide future attempts at nonautoantigen primary prevention.
Autoantigen primary prevention
Autoantigen-specific primary prevention would address the question of whether immunological tolerance induced against insulin, GAD65, IA-2 or the ZnT8 transporter could prevent the development of islet auto immunity against these autoantigens-currently measured as the appearance of auto antibodies. The appropriate participants of such trials would be children with a high genetic risk of developing islet auto immunity or T1DM. Selecting children with the HLA-DQ DR4-DQ8/DR3-DQ2 genotype would represent about 3-4% of all newborn babies, which would correspond to ~27% of all children who would be diagnosed with T1DM before 18 years of age. 4 The selection of children with a HLA-DQ DR4-DQ8/DR3-DQ2 genotype born in families with a mother, father or sibling with T1DM would narrow down the inclusion criteria further to a group of children with high risk of early age at onset of islet autoimmunity. The proposed treatment in this group of children would need to have a very high safety profile, as only a small fraction of the children included would be expected to develop islet autoimmunity or T1DM, or both.
One primary prevention trial, Primary Intervention with Oral Insulin for Prevention of T1DM (Pre-POINT) is underway in infants with a very high genetic risk of developing T1DM. 25 The children have the HLA-DQ DR4-DQ8/DR3-DQ2 genotype and had one parent with T1DM. The rationale is to use insulin in an attempt to induce immunological tolerance to prevent the appearance of insulin autoantibodies. Pre-POINT is ongoing and both oral and nasal insulin will be tested in genetically predisposed children aged from 18 months to 7 years with no islet autoimmunity. Pre-POINT will be testing oral insulin at a dose almost 10 times that used in the Diabetes Prevention Trial Type 1 (DPT-1). The DPT-1 trial failed to find an effect of oral insulin. 26 A debate is ongoing as it whether it is ethical to include children in this type of randomized, controlled clinical trial when understanding of the future consequences of exposing infants to mucosal insulin is unknown. 
Secondary prevention
Secondary prevention trials have been carried out for the past 20 years with little success in terms of prevention. However, these trials have provided novel observations that aid understand of the disease process in children who have developed islet autoantibodies, and also demonstrate that large-scale, multicentre secon dary prevention trials are possible. The DPT-1 trial recruited relatives of patients with T1DM throughout the USA and Canada.
Additional secondary prevention trials are now easier to conduct as efficient HLA-DR-DQ genotyping and standardized islet autoantibody tests are available. HLA genotyping makes it possible to confirm that an individual to be included in a randomized controlled secondary prevention trial has the stipulated genetic risk for T1DM. For example, individuals with the HLA-DQ A1*01:02-B1*06:02 haplotype could be excluded because this haplotype is rarely seen among patients with T1DM <12 years of age. Future investigations may need to take into account that the development of islet auto antibodies is related to the HLA-DQ genotype. For example, HLA-DQ8 is associated with an increased risk of developing T1DM with insulin, IA-2 or ZnT8A autoantibodies. By contrast, HLA-DQ2 is associated with an increased risk of GAD65 autoantibodies but a decreased risk of IA-2 autoantibodies, and HLA-DQ6.4 is associated with an increased risk of developing T1DM with ZnT8A autoantibodies. 27 In the secondary prevention approach, a nonautoantigen-specific treatment or treatment with any of the four specific islet autoantigens is used to test whether immunomodulating agents halt the progression to clinical onset of T1DM in individuals with islet autoantibody-positivity.
Nonautoantigen secondary prevention
Nonantigen-specific agents have been tested in a number of secondary prevention trials. Ciclosporin was given to first-degree relatives of patients with T1DM who were positive for islet cell autoantibodies. The treatment did not reduce the progression to clinical onset of the disease. 28 Bacillus Calmette-Guérin (BCG) vaccine was given to a group of patients with islet auto immunity. 29 The hypothesis was that this treatment, associated with a marked nonspecific stimulation of the immune system, would halt progression to T1DM. No evidence was found that BCG vaccination could prevent β-celldamaging processes leading to T1DM in genetically at-risk children. Ketotifen was administered to islet autoantibody-positive individuals. 30 The study tested if the anti-oedematous therapy with this histamine antagonist would preserve β-cell function. The treatment did not induce protection. 30 Nicotinamide was tested in two large clinical trials. 31, 32 On the basis of animal studies, nicotinamide was thought to halt progression to T1DM. The outcome of these two trials showed that the treatment had no effect. Finally, a gluten-free diet was tested, as gluten exposure was thought to modulate the risk of the develop ment of islet autoantibodies among first-degree relatives of patients with T1DM; however, the diet had no effect. 33, 34 In the BABYDIET studies, a gluten-free diet was given to islet autoantibody-positive children without any notable preventive effect on the risk of T1DM. 35 Autoantigen-specific secondary prevention Insulin therapy in individuals with islet autoimmunity has been suggested to be advantageous for two reasons. First, insulin would reduce the β-cell load in the state of subclinical T1DM. Second, insulin would possibly induce immunological tolerance. Treatment with insulin has been tested either as parenteral, oral or intranasal insulin. Evidence of delayed disease progression was obtained in pilot studies that tested parenteral insulin (subcutaneously and intravenously) as prophylaxis among first-degree relatives of patients with T1DM who had islet cell autoantibodies. 36 In retrospect, this pilot was complicated by the fact that some of the participants who showed a delayed onset were later found to have protective HLA genotypes. 37 
Parenteral insulin
In the DPT-1 trial, >80,000 first-degree relatives of patients with T1DM were screened for islet cell antibodies. 26 The intervention consisted of low-dose subcutaneous ultralente insulin, administered twice daily to a total dose of 0.25 units per kg body weight per day. At this dose, no delay or prevention of T1DM was observed. 26 The parenteral arm of this randomized controlled trial, there fore, failed to reproduce the results of the pilot studies. As only one dose of insulin was tested and the participants already showed reduced β-cell function at the time of randomization, it was not possible to determine whether the administered insulin had any effect on protecting the survival of the β cells, inducing immunomodulation, or both. Nevertheless, the DPT-1 trial demon strated the feasibility of screening for individuals with T1DM genetic susceptibility and islet autoimmunity.
Oral insulin DPT-1 participants with islet cell antibodies and positivity for insulin autoantibodies with no sign of impaired glucose tolerance were randomly allocated to receive oral insulin (7.5 mg per day) or placebo. 38 The original study failed to demonstrate that oral insulin delayed the clinical onset of T1DM. 38 A post hoc analysis revealed a subgroup of individuals with high-titre insulin autoantibodies who experienced a considerable delay in clinical onset of T1DM. 38 Follow-up for 13 years of the participants with high-titre insulin autoantibodies who took oral insulin suggested that the preservation of β-cell function was maintained for as long as the oral insulin was taken. 39 TrialNet, an international network exploring ways to prevent, delay or reverse progression of T1DM, is currently recruiting participants to continue to test whether oral insulin is effective in the prevention of T1DM in individuals with relatives with T1DM.
Nasal insulin
Insulin has also been used nasally in secondary prevention trials in attempts to induce immune tolerance. In the Intranasal Insulin Trial (INIT), at phase I and II stages, a double-blind, crossover design was used to study Australian individuals with insulin autoantibodies and first-degree relatives with T1DM. INIT-I was completed in 2004. No significant effects on β-cell function were observed, but the findings did indicate improved immune tolerance to insulin. 40 INIT-II is an ongoing randomized, double-blind, placebo-controlled trial using nasal insulin at either 1.6 mg or 16 mg and aims to assess the effects of nasal insulin on islet autoimmunity.
The Diabetes Prediction and Prevention (DIPP) trial in Finland was a double-blind trial using nasal insulin in children with genetic risk of T1DM who were positive for islet cells and insulin autoantibodies. 41 In 224 children, short-acting insulin or placebo was administered intranasally once a day, but no protective effect was seen, 41 nor did the nasal insulin modulate the characteristics of the insulin autoantibodies, which indicated that the insulin autoimmunity was already mature at the beginning of the intervention. 42 The importance of the INIT and DIPP trials is that they demonstrated the safety of nasal insulin. Furthermore, the ancillary or mechanistic studies conducted as part of these trials demonstrated signs of immune tolerance to insulin with administration of nasal insulin. Future studies should include broader dose-response analyses and take into account that the immune response to autoantigen might be closely related to the HLA-DQ genotype of the individual. In other words, insulin alone might not be sufficient when, at the same time, islet autoimmunity is spreading to IA-2A, GADA, or both.
Glutamic acid decarboxylase
Glutamic acid decarboxylase (GAD65) is another major autoantigen involved in the development of T1DM. Whereas insulin autoimmunity affects mainly the young, GAD65 autoimmunity is less sensitive to age. Alumformulated recombinant human GAD65 has been tested in phase II and III clinical trials and found to be safe. [43] [44] [45] [46] In one ongoing trial that will be completed in 2015, a total of 50 children have been randomly allocated to receive either placebo or alum-formulated GAD65 via two injections 1 month apart. As yet, no drug-related adverse events have been reported.
At baseline, the children were heterogeneous in terms of β-cell function (Figure 3 ). Some children with GAD65 and at least one or more islet autoantibody already showed β-cell function derangements. Eight children had reduced first phase insulin release, five had impaired glucose tolerance after an oral glucose tolerance test and four children had reduced capacity to clear plasma glucose (Figure 3) . However, only two children were abnormal in all three tests and four others shared at least two abnormalities. These data suggest that β-cell control of blood glucose varies markedly between children with at least two islet autoantibodies. This observation is important when secondary prevention trials are designed. Inclusion criteria must be well defined to secure a homogeneous study population to increase the odds of detecting effects on β-cell function by the intended treatment.
Intervention trials
Tertiary prevention, or intervention, trials recruit patients newly diagnosed with T1DM. The aim of these trials is to preserve levels of C-peptide detected at the time of clinical diagnosis; in other words, to preserve residual β-cell function. The results of the first intervention trial were reported in 1978 in three patients with T1DM treated with prednisone and azathioprine. 47 After the demonstration a few years earlier that T1DM was an auto immune disease, immunosuppression was tested as it was hypo thesized to be beneficial. Numerous openlabel and small studies followed. Essentially, all immunosuppressive agents that came to the market were tested on patients with T1DM. 48 None of these many drugs convincingly preserved the residual β-cell function present at the time of clinical diagnosis. Adverse effects were common.
Intensive insulin regimens for the treatment of patients with new-onset T1DM were initially proposed as a means to preserve the remaining β cells and enhance their functionality. 49 Intensive insulin treatment is, there fore,
FPIR <30 2 h glucose, OGTT <7.8 Figure 3 | β-cell control of blood glucose varies markedly between children with at least two islet autoantibodies. Venn-diagram of 21 children with GAD65 autoantibodies and at least one more islet autoantibody, which illustrates the different findings of baseline β-cell function tests. The number of children with impaired oral glucose tolerance tests was eight, the number with reduced first-phase insulin release following an intravenous glucose tolerance test was 11, and the number of children with a k-value <1.50 in a glucose clearance rate test was seven. Only one child was abnormal in all three tests and three children were abnormal in two of the tests. Abbreviations: FPIR, first-phase insulin release; OGTT, oral glucose tolerance test.
used as the basic therapy for all patients newly diagnosed with T1DM who are included in intervention trials. Most investigators have a set goal to manage the T1DM of the patient: to reach HbA 1c levels that are as close to normal as possible. Regardless of the treatmentnonautoantigen-specific or autoantigen-specific-insulin treatment will have to be taken into account.
Nonautoantigen intervention
Nonautoantigen-specific drugs have been tested in several controlled and noncontrolled studies. Controlled clinical trials have been carried out with specific immuno suppressive agents, including anti-CD3 monoclonal antibodies. The following is a brief summary of the rationale of using nonautoantigen intervention in recent or ongoing trials.
The Prevention of Diabetes Progression Trial 50 is an ongoing phase II trial testing the safety of daclizumab, which is an immunosuppressive, humanized IgG1 that binds specifically to the α subunit of the human highaffinity IL-2 receptor of T cells. The outcome will be of considerable interest as another study found that a genetic variant of the IL-2 receptor was associated with T1DM in genome-wide association studies. 3 Several trials have been carried out with anti-CD3 monoclonal antibodies. 14, 51 In the past decade, two humanized, anti-CD3 monoclonal antibodies have been extensively studied, otelixizumab 52, 53 and teplizumab. [54] [55] [56] The phase II trial with otelixizumab, a nonmitogenic anti-CD3 monoclonal antibody, in patients newly diagnosed with T1DM suppressed the rise in insulin requirements over 48 months, but the effect was related to age and residual C-peptide at diagnosis. 52 The subsequent phase III trial (Durable Response Therapy Evaluation for Early or New-Onset Type 1 Diabetes, DEFEND) used a cumulated dose of 3 mg, as compared to 48 mg for the phase II study. As the end point of this lower-dose study was not reached both DEFEND and DEFEND-2 were terminated. The 4-year follow-up of the patients in the phase II clinical trial indicated a delay of increased insulin requirements of patients. 52 Furthermore, in a subgroup of the patients in the phase II trial, the capacity to make antibodies to tetanus toxoid (a recall immunity test) was preserved, which adds to the aspect of safety. 57 Treatment with teplizumab, another anti-CD3 monoclonal antibody, resulted in improved C-peptide responses and clinical parameters in T1DM for at least 2 years in the absence of continued immunosuppressive medications in one study. 56 The subsequent phase III clinical trial, PROTÉGÉ, had modified end points, as the primary composite outcome was the percentage of patients with insulin use of <0.5 U/kg per day and an HbA 1c level of <6.5% at 1 year. 58 Although the composite end point was not met, 5% of patients in the teplizumab groups were not taking insulin at 1 year, compared with no patients not taking insulin in the placebo group. 54 Mechanistic studies suggest it is possible to monitor antigen-specific T cells after teplizumab treatment, 59 which should be encouraged in future clinical trials. The fact that industry-conducted trials such as DEFEND-1, DEFEND-2 and PROTÉGÉ have been discontinued and recruitment suspended is a distinct drawback to progress, and leaves patient results and follow-up data unavailable for further analyses.
TrialNet conducted a Phase II study of rituximab (a CD20 monoclonal antibody) in patients newly diagnosed with T1DM. 60 A total of 87 patients of 8-40 years of age were randomly allocated to receive rituximab or placebo; rituximab was administered on days 1, 8, 15 and 22 of the study. The mean area under the curve for the C-peptide level after a mixed meal tolerance test at 1 year was significantly higher in the patients treated with rituxi mab than in those who received placebo. The effects of this B-lymphocyte monoclonal antibody was a surprise to some researchers, as T1DM is usually regarded as a T-cell-mediated disease. The results underscore the need for further studies on the role of B lymphocytes in the maintenance of chronic islet autoimmunity.
In mice, cross-presentation of autoantigens to CD8 + T cells precipitates diabetes mellitus. 61 In humans, rituximab blocks the immune response to neoantigens 62 but does not affect already established autoantibodies such as GADA and IA-2A. 63 However, levels of insulin antibodies and recall antigen antibodies are reduced by rituximab therapy. 62 The observations on autoantibody and neo antigen responses underscores the importance of the B cell as an antigen-presenting cell that interacts not only with T-helper cells but also directly with other antigen-presenting cells, such as with dendritic cells to induce autoantibody formation (Figure 4) . However, as the safety of rituximab is of major concern (the drug compromises the patient's capacity to mount an immune response to infectious agents), the future use of this monoclonal antibody in intervention studies requires thoughtful consideration. Other approaches targeting the antigen-presenting cell-B cell or the B cell-T cell synapses will be of considerable interest, as it is still unclear whether inhibition of islet autoantibody formation will be associated with preserved β-cell function (Figure 4) . IL-1β has long been considered a cytokine that is cytotoxic to β cells. Anakinra is an IL-1β receptor antagonist used to treat rheumatoid arthritis. This drug was administered daily for 28 days to 15 children within 1 week of diagnosis of T1DM. The children were then followed up for 6 months. Anakinra was well tolerated; however, the drug did not preserve β-cell function. 64 The future use of anakinra in intervention trials is unclear. The AntiInterleukin-1 in Diabetes Action trial and a study by TrialNet are testing the use of either anakinra or canakinumab, which is a human monoclonal antibody to IL-1β. The possible use of anakinra in combination trials will depend on its safety profile in children and young adults.
A number of BCG studies have been completed showing some 65 or no 66,67 preservation of C-peptide levels in patients newly diagnosed with T1DM. An ongoing human trial is focused on establishing a possible reduction in self-reactive T lymphocytes with BCG treatment. Initial findings of a proof-of-concept study of this trial have reporting increased levels of C-peptide in 2 of 16 patients with long-term T1DM. 68 The variable outcome with BCG vaccine studies could be due to the fact that BCG is a live vaccine with very variable composition between manufactures and production lots. Anti-thymocyte globulin was found to induce shortterm benefits in the NOD mouse, primarily by inducing immunoregulation rather than depletion of T cells. In humans, anti-thymocyte globulin is thought to decrease insulin requirement in patients with new-onset T1DM; however, serious adverse effects such as transient thrombocytopenia are major drawbacks. In the Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Dia betes phase II study, anti-thymocyte globulin was administered daily to patients of >12 years of age newly diagnosed with T1DM in escalating doses over 4 days. The end point of this trial is a mixed meal tolerance test for C-peptide levels after 12 months of T1DM. This trial and a second clinical trial of anti-thymocyte globulin are ongoing.
TrialNet initiated a study of abatacept with the rationale of determining whether treatment with the fusion pro tein of cytotoxic T-lymphocyte protein 4 and immuno globu lin (CTLA4-Ig) in patients newly diagnosed with T1DM would preserve mixed meal tolerance test stimulated C-peptide levels. CTLA4 is thought to be involved in modulating immune responses by inducing co-stimulatory signals, which are important for T-lymphocyte activation. CTLA4-Ig is proposed to regulate, but not destroy, T lymphocytes by inhibiting their stimulatory pathway of activation and is, therefore, considered relatively safer than other immunosuppressive agents. The first report of this phase II clinical trial demon strated that adjusted C-peptide area under the curve was significantly higher at 2 years with abatacept than with placebo. 69 The researchers concluded that abatacept initially preserved β-cell function, but that the decrease in β-cell function after the 6-month time point in the abatacept group was parallel to that in the placebo group. DiaPep277® (Andromeda Biotech Ltd, Ness Ziona, Israel) is a synthetic peptide of 24 amino acids related to heat shock protein 60 and has immunomodulatory charac teristics. The mechanisms of action are not fully clarified. Treatment with DiaPep277® has been shown to be safe in adults. Two Phase III clinical trials of DiaPep277® are underway, one study in children newly diagnosed with T1DM and another study in adults newly diagnosed with T1DM to test whether DiaPep277® preserves residual C-peptide levels. Meal-stimulated C-peptide level will be tested during 2 years of follow-up after 10 injections of DiaPep277® or placebo. Additional clinical trials are planned. 70 Autoantigen-specific interventions A phase I clinical trial with the altered peptide ligand of insulin, NBI-6024, in patients newly diagnosed with T1DM has been completed. 71 NBI-6024 is a vaccine to the 9-23 amino acid region of the insulin B chain and is thought to be able to shift induction of T cells from inflammatory T-helper type 1 lymphocytes that produce IFN-γ into T-helper type 2 regulatory T cells.
However, treatment with NBI-6024 at repeated doses of 0.1, 0.5 or 1.0 mg did not improve or maintain β-cell function. Further studies on the approach to modulate the au toimmune response to proinsulin and insulin are needed.
The proinsulin DNA vaccine BHT-3021 is a plasmid encoding proinsulin that was designed to tolerize the immune system to proinsulin. This drug was tested in a randomized, blinded, placebo-controlled multicentre study. 72 The rationale is to test whether expression of this plasmid in vivo produces proinsulin that is able to reverse the autoimmune process as related to insulin. The study has been completed but results are yet to be reported.
Alum-formulated recombinant human GAD65 was tested in phase II clinical trials, and had some positive effects in terms of preserving residual C-peptide levels. 44, 45 The autoantigen-based therapy was also tested in an additional phase II trial with a dose-regimen that differed from that in the previous two trials. 46 In this trial, two or three doses of subcutaneous GAD65-alum administered over 4-12 weeks did not alter the C-peptide disappearance rate during 12 months of follow up in patients newly diagnosed with T1DM. Similar failure to affect the C-peptide dis appearance rate over 15 months follow-up was found in a phase III study. 73 The lack of effects of the GAD65-alum approach has complicated further clinical investigations. Induction of T regulatory cells were reported in the phase II clinical trials 43, 74 These types of analyses are still to be reported in the phase III clinical trials.
Combination interventions
Some experts argue that monotherapy in patients newly diagnosed with T1DM will be insufficient, as islet autoimmunity against several autoantigens developed several years before the clinical onset of the disease. The transient immunosuppression of the monotherapies currently being tested might, however, be made more durable by the use of combination therapy. Effects of combination therapies have been reported in two studies.
The Immune Tolerance Network combined treatment with a recombinant form of human IL-2 and sirolimus (rapamycin) in a phase I trial. The rationale was that this drug combination was found to be effective for long-term prevention of diabetes mellitus in the NOD mouse. The study was an open-label, uncontrolled safety trial. 75 Participants were adults of 18-45 years of age who had been diagnosed with T1DM within the past 4 years. Concentrations of T regulatory cells increased within the first month of therapy; however, clinical and metabolic data demonstrated a transient worsening in all participants; in other words, the drug combination had a worse effect than placebo. The authors conclude that their results highlight the difficulties in translating therapies tested in animal studies to humans. 75 The combination of mycophenolate mofetil and daclizumab (an anti-IL2 receptor monoclonal antibody) was tested in a multicentre, three-arm, randomized, doublemasked, placebo-controlled clinical trial carried out by TrialNet. Participants were patients of 8-45 years of age who had been diagnosed with T1DM within the past 3 months. This trial was carried out to assess whether this combination would preserve the residual β-cell function. 76 However, neither mycophenolate mofetil alone or in combination with daclizumab had an effect on the loss of β-cell function. 76 Adverse events were common and the safety of this combination therapy needs careful consideration especially as the drug combination induced activation of Epstein-Barr virus, an infection associated with lymphoma.
Other combination therapies might be worth consider ing for future intervention trials. For example, agents with strong adjuvant effects such as a BCG vaccine could be combined with an autoantigen-based therapy, such as alum-formulated recombinant human GAD65 or the proinsulin DNA vaccine BHT-3021. An immunomodulation event might be enabled by the combination therapy that is not possible with the monotherapy.
Future directions
Completed and ongoing secondary prevention and intervention trials show little promise of achieving the major end point of preserving β-cell function. The rationale and design of these trials has often been based on the preclinical findings in animal studies, which could be misleading because the aetiology and pathogenesis of spontaneous autoimmune diabetes mellitus in the NOD mouse or BB rat is different from that of the early stages of T1DM in humans. Future primary prevention or secon dary prevention trials should be designed on the basis of what is known in humans about the early stages of the aetiology and pathogenesis of T1DM.
None of the many immunosuppressive agents tested so far have preserved β-cell function in the long-term in patients with either T1DM or in individuals with islet autoantibodies. At best, transient effects have been observed but further studies have had to be abandoned due to safety issues or severe adverse effects of the immuno suppressive drugs. 54 Safety remains a major concern in clinical trials with immunosuppressive agents. The risk-benefit analysis needs to take into account the fact that an almost normal life can be lived by an in dividual with T1DM treated by daily insulin injections.
The different approaches of autoantigen administration have revealed effects on secondary end-point measures, such as increased numbers of T-regulatory cells. It is hypothesized that preservation of β-cell function may be associated with such cells. Although β-cell function has not been fully preserved 45 and reproducible 46, 73 these high safety studies make it possible to design trials to evaluate dose and exposure-dependent parameters. Combination therapy with, for example, proinsulin and GAD65, alone and in combination should make it possible to evaluate the immune response to these au toantigens, particularly in secondary prevention trials.
Immunomodulation with autoantigen possibly combined with immunosuppressive therapy has been much debated in relation to rodent studies. 77 When future human studies are planned, it is important that attention is given to the HLA genotype of the individuals. People with different HLA-DQ risk alleles might show different reactivity to an autoantigen. Although CD4 + T cells expressing T-cell receptors that recognize autoantigen peptides presented on HLA-DR or HLA-DQ heterodimers remain an undisputable target for prevention, it seems equally important that attention should shift from T cells as the sole target to B cells as a target. As shown in ex vivo experiments, B cells are effective antigenpresenting cells. 78, 79 Recent studies in mice provide evidence that there is cross-talk between B lymphocytes and CD8 + effector T cells that might lead to diabetes mellitus. 61 The chronic autoimmune response in individuals with islet autoantibodies might be best treated by eradicating the B cells or plasma cells that continue to produce islet autoantibodies. Targeting such B cells might also be an effective secondary prevention therapy. In this regard, studies in patients with latent autoimmune diabetes mellitus in the adult (LADA) might be useful. Newly diagnosed patients with T1DM >18 years but <35 years of age and patients with LADA above 35 years of age are expected to outnumber patients with T1DM younger than 18 years of age at least by a factor of three, at least in Sweden. 80 Although C-peptide levels might not be as sensitive an outcome as in studies of children, this deficiency might be countered by selecting participants with similar baseline levels. 80 TrialNet and the Immune Tolerance Network are international networks supported by the NIH. Both networks have established an infrastructure for trials for predicting and preventing T1DM. Within these networks, relatives of patients with T1DM are screened for disease risk and then either followed up for the disease natural history or, if possible, included in clinical trials. How ever, only about 13-15% of patients newly diagnosed with T1DM have a first-degree relative with the dis ease. Individuals in the general population found to be at high risk of developing T1DM owing to their HLA-DQ genotype could also be included in the screening effort. Current screening technology for both HLA-DQ typing and islet autoantibody analyses have sufficiently high capacity for screening the general population. 24 Children and young adults screened and found to have multiple auto antibodies would then be eligible for inclusion in secondar y prevention studies.
Investigator-initiated clinical trials are needed to carry out smaller and more efficient studies. Such trials need to have elements of dose-escalation, route of administration and more immunological outcomes than used to date. We need to obtain therapy that is able to reduce islet autoantibodies to test the hypothesis that the presence of islet autoantibodies reflect an ongoing, chronic au toimmune disease directed against the pancreatic β cells.
Conclusions
In conclusion, primary prevention studies are the major goal in the future, and would aim to induce immunological tolerance to islet autoantigens. Genotyping for HLA-DQ and HLA-DR risk alleles and non-HLA risk alleles should make it possible to identify indi viduals at increased risk to avoid overtreatment. Nonautoantigen primary prevention trials may not be productive. Completed secondary prevention and intervention trials show little promise of achieving the major end point of preserving β-cell function. Immunomodulation with autoantigen combined with immunosuppressive therapy, if safe, needs to be considered. An immunomodulation event may be enabled by a combination therapy that is not possible with the monotherapy. Future human studies with autoantigens should take the HLA genotype of the individuals into account, as HLA molecules control antigen presentation. Of equal importance, attention should shift from T cells as the sole target to B cells as a target. Ancillary or mechanistic studies, in particular of T cells, B cells, natural killer cells and monocytes in blood, may be important to further understand immune responses to islet autoantigens in secondary prevention as well as in intervention studies. A distinct possibility for future studies will be to combine alumformulated insulin with alum-formulated recombinant human GAD65, or combine oral or nasal insulin with oral or nasal GAD65, for primary prevention, secondary pr evention as well as intervention studies.
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